Cargando…

Study on the prognosis, immune and drug resistance of m6A-related genes in lung cancer

BACKGROUND: Few studies have demonstrated that the relationship between m6A-related genes and the prognosis, tumor microenvironment and drug resistance of LC. METHODS: The main results were analyzed with bioinformatics methods. RESULTS: Hence, we found 10 m6A-related genes expressed less in tumor sa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Yang, Qian, Zhouyao, Feng, Mingyang, Liao, Weiting, Wu, Qiuji, Wen, Feng, Li, Qiu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583491/ https://www.ncbi.nlm.nih.gov/pubmed/36261786 http://dx.doi.org/10.1186/s12859-022-04984-5

Ejemplares similares

Comprehensive analysis of EMT-related genes and lncRNAs in the prognosis, immunity, and drug treatment of colorectal cancer
por: Yang, Yang, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Fourth- or Further-Line Ripretinib in Advanced Gastrointestinal Stromal Tumors
por: Liao, Weiting, et al.
Publicado: (2021)

The Effects of Autophagy-Related Genes and lncRNAs in Therapy and Prognosis of Colorectal Cancer
por: Yang, Yang, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumor: A Systematic Review
por: Feng, Mingyang, et al.
Publicado: (2022)

Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma
por: Wu, Qiuji, et al.
Publicado: (2022)

Histone acetylation-related IncRNA: Potential biomarkers for predicting prognosis and immune response in lung adenocarcinoma, and distinguishing hot and cold tumours
por: Li, Rumeng, et al.
Publicado: (2023)

Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer From the US and Chinese Perspectives
por: Wu, Qiuji, et al.
Publicado: (2020)

Cost-effectiveness analysis of adjuvant treatment for resected pancreatic cancer in China based on the ESPAC-4 trial
por: Huang, Jiaxing, et al.
Publicado: (2018)

N6-methyladenosine methylation related immune biomarkers correlates with clinicopathological characteristics and prognosis in clear cell renal cell carcinoma
por: Huang, Zhilong, et al.
Publicado: (2022)

Pancancer analysis of the correlations of HS6ST2 with prognosis, tumor immunity, and drug resistance
por: Chen, Weiwei, et al.
Publicado: (2023)

N6-Methyladenosine (m(6)A)-Related lncRNAs Are Potential Signatures for Predicting Prognosis and Immune Response in Lung Squamous Cell Carcinoma
por: Zhou, Yang, et al.
Publicado: (2022)

A Novel M6A-Related Genes Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma
por: Wang, Xuewen, et al.
Publicado: (2022)

Identification of a novel m5C/m6A-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma
por: Ma, Yiming, et al.
Publicado: (2022)

Identification of Two m6A Readers YTHDF1 and IGF2BP2 as Immune Biomarkers in Head and Neck Squamous Cell Carcinoma
por: Li, Shaojie, et al.
Publicado: (2022)

Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer
por: Wang, Yi, et al.
Publicado: (2022)

m6A-immune-related lncRNA prognostic signature for predicting immune landscape and prognosis of bladder cancer
por: Feng, Zi-Hao, et al.
Publicado: (2022)

A novel LUAD prognosis prediction model based on immune checkpoint-related lncRNAs
por: Liu, Yang, et al.
Publicado: (2022)

A Risk Score Model Incorporating Three m6A RNA Methylation Regulators and a Related Network of miRNAs-m6A Regulators-m6A Target Genes to Predict the Prognosis of Patients With Ovarian Cancer
por: Li, Qian, et al.
Publicado: (2021)

A Risk-Assessing Signature Based on Hypoxia- and Immune-Related Genes for Prognosis of Lung Adenocarcinoma Patients
por: Wang, Yue, et al.
Publicado: (2022)

Identification and verification of m6A-related miRNAs correlated with prognosis and immune microenvironment in colorectal cancer
por: Qiu, Xinze, et al.
Publicado: (2023)

Inclusion of interleukin-6 improved the performance of postoperative acute lung injury prediction for patients undergoing surgery for thoracic aortic disease
por: Li, Huili, et al.
Publicado: (2023)

Construction of an m6A-related lncRNA model for predicting prognosis and immunotherapy in patients with lung adenocarcinoma
por: Shen, Hong-Yu, et al.
Publicado: (2023)

The role of m6A-related genes in the prognosis and immune microenvironment of pancreatic adenocarcinoma
por: Tang, Rong, et al.
Publicado: (2020)

The m(6)A-related gene signature for predicting the prognosis of breast cancer
por: Zhong, Shanliang, et al.
Publicado: (2021)

IRGS: an immune-related gene classifier for lung adenocarcinoma prognosis
por: Shi, Xiaoshun, et al.
Publicado: (2020)

CLEC4M is associated with poor prognosis and promotes cisplatin resistance in NSCLC patients
por: Tan, Li-Ming, et al.
Publicado: (2019)

Potential prognosis index for m(6)A-related mRNA in cholangiocarcinoma
por: Zhu, Huaqiang, et al.
Publicado: (2022)

A five-cuproptosis-related LncRNA Signature: predicting prognosis, assessing immune function & drug sensitivity in lung squamous cell carcinoma
por: Zhao, Hongtao, et al.
Publicado: (2023)

N6-methylandenosine-related immune genes correlate with prognosis and immune landscapes in gastric cancer
por: Huang, Yuancheng, et al.
Publicado: (2022)

The m6A/m5C/m1A regulator genes signature reveals the prognosis and is related with immune microenvironment for hepatocellular carcinoma
por: Liu, Ting, et al.
Publicado: (2023)

A multi-omics analysis reveals CLSPN is associated with prognosis, immune microenvironment and drug resistance in cancers
por: Chen, Yihong, et al.
Publicado: (2023)

A Novel Immune-Related Gene Signature Predicts Prognosis of Lung Adenocarcinoma
por: Ma, Chao, et al.
Publicado: (2022)

Identification of a N6-Methyladenosine (m6A)-Related lncRNA Signature for Predicting the Prognosis and Immune Landscape of Lung Squamous Cell Carcinoma
por: Weng, Chengyin, et al.
Publicado: (2021)

M6AREG: m(6)A-centered regulation of disease development and drug response
por: Liu, Shuiping, et al.
Publicado: (2022)

The Role of m6A RNA Methylation-Related lncRNAs in the Prognosis and Tumor Immune Microenvironment of Papillary Thyroid Carcinoma
por: Wang, Wenlong, et al.
Publicado: (2022)

Mechanisms of resistance to immune checkpoint inhibitors and strategies to reverse drug resistance in lung cancer
por: Qian, Fang-Fei, et al.
Publicado: (2020)

Effect of N6-methyladenosine (m6A) regulator-related immunogenes on the prognosis and immune microenvironment of breast cancer
por: Yu, Zhun, et al.
Publicado: (2022)

Development and validation of an immune‐related gene signature for prognosis in Lung adenocarcinoma
por: Guo, Zehuai, et al.
Publicado: (2023)

Analysis of m6A-Related lncRNAs for Prognosis Value and Response to Immune Checkpoint Inhibitors Therapy in Hepatocellular Carcinoma
por: Wang, Yi, et al.
Publicado: (2021)

Identification of novel immune-related molecular subtypes and a prognosis model to predict thyroid cancer prognosis and drug resistance
por: Zhang, Wei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ikd5jf7kp6evkloiqqsnrh4k54